Pfizer and Eli Lilly Announce Positive Phase 3 Clinical Results for Ulcerative Colitis

Ulcerative colitis is a chronic, systemic, inflammatory disease caused by inflammation of the large intestine, which causes abdominal pain, bloody diarrhea, severe urgency to defecate, weight loss, and fatig.

50% of patients achieved clinical remission after 1 year, Lilly IL-23 inhibitor showed long-term efficacy

Eli Lilly and Company announced that its monoclonal antibody mirikizumab, which targets the p19 subunit of IL-23, has achieved positive results in a Phase 3 clinical tri.

Almost all (98%) patients who received mirikizumab and achieved clinical remission after 1 year had not received corticosteroids for at least 3 mont.

Eli Lilly has submitted regulatory applications for mirikizumab for the treatment of ulcerative colitis with the US FDA and EU EMA, with responses expected in 202

Pfizer S1P receptor modulator shows 'best-in-class' potential

Pfizer today announced detailed results from two Phase 3 clinical trials of the selective sphingosine 1-phosphate (S1P) receptor modulator etrasim.

Etrasimod was developed by Arena Pharmaceuticals, which Pfizer completed its acquisition of in Mar.

Michael Corbo, Chief Development Officer, Inflammation and Immunology, Pfizer, said: "Patients with ulcerative colitis often require multiple options to manage their disease, and there is a significant need for new treatmen.

References:

[1] Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Stu.

[2] Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colit.